INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Systematic review / meta-analysis / 2020

A systematic review indicates NAD+ precursors show favorable outcomes in age-related disorders, but long-term human trial evidence remains limited.

A systematic review evaluated the potential health and longevity benefits of increasing NAD+ levels across Medline, Embase, and PubMed. A total of 147 articles (113 preclinical and 34 clinical) met the inclusion criteria. Most studies reported that NAD+ precursors (NAM, NR, NMN, and to a lesser extent NAD+ and NADH) showed favorable outcomes on several age-related disorders tied to oxidative stress, inflammation, and mitochondrial impairment. However, evidence remains quite limited, long-term human trials are nascent, and potential risks include the accumulation of toxic metabolites, tumorigenesis, and cellular senescence.

Study type
Systematic review
Who was studied
147 included articles (113 preclinical and 34 clinical)
What was measured
Health and/or longevity benefits and safety of raising NAD+ levels

THE PAPER

NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis.

Braidy N, Liu Y. Exp Gerontol, 2020.

PubMed 31917996 ↗DOI 10.1016/j.exger.2020.110831 ↗

Nutrients & adequacyHealthy aging & longevity

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.